Oestrogen receptor status and survival in women with BRCA2-associated breast cancer

Kelly Metcalfe, Henry T. Lynch, William D. Foulkes, Nadine Tung, Olufunmilayo I. Olopade, Andrea Eisen, Jordan Lerner-Ellis, Carrie Snyder, Shana J. Kim, Ping Sun, Steven A. Narod

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: To evaluate the predictors of mortality, including ER status, in women with a BRCA2 mutation and breast cancer. Methods: Eligible participants were identified from within two longitudinal cohorts. These patients were selected because they were diagnosed with breast cancer between 1975 and 2015 and carried a BRCA2 mutation. Data were abstracted from the medical record and pathology report. We analysed the effects of ER status and other variables on breast cancer specific survival using a Cox proportional hazards model. Results: Three hundred ninety women with breast cancer and a BRCA2 mutation were included in the analysis. The mean follow-up time was 12.3 years (range 1–39 years) and 89 subjects died (22.8%). In the multivariate analysis, women with ER-positive tumours were more likely to die than women with ER-negative tumours (HR 2.08, 95% CI 0.99–4.36, p = 0.05), and this was of borderline significance. For the 233 women with ER-positive tumours the 20-year survival rate was 62.2%, compared to 83.7% for 58 women with ER-negative tumours (p = 0.03). Conclusions: The majority of women with a BRCA2 mutation present with ER-positive breast cancer, and for these women, prognosis may be worse than for BRCA2 carriers with ER-negative breast cancer.

Original languageEnglish (US)
JournalBritish Journal of Cancer
DOIs
StatePublished - Jan 1 2019

Fingerprint

Estrogen Receptors
Breast Neoplasms
Survival
Mutation
Neoplasms
Women's Rights
Proportional Hazards Models
Medical Records
Multivariate Analysis
Survival Rate
Pathology
Mortality

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. / Metcalfe, Kelly; Lynch, Henry T.; Foulkes, William D.; Tung, Nadine; Olopade, Olufunmilayo I.; Eisen, Andrea; Lerner-Ellis, Jordan; Snyder, Carrie; Kim, Shana J.; Sun, Ping; Narod, Steven A.

In: British Journal of Cancer, 01.01.2019.

Research output: Contribution to journalArticle

Metcalfe, K, Lynch, HT, Foulkes, WD, Tung, N, Olopade, OI, Eisen, A, Lerner-Ellis, J, Snyder, C, Kim, SJ, Sun, P & Narod, SA 2019, 'Oestrogen receptor status and survival in women with BRCA2-associated breast cancer', British Journal of Cancer. https://doi.org/10.1038/s41416-019-0376-y
Metcalfe, Kelly ; Lynch, Henry T. ; Foulkes, William D. ; Tung, Nadine ; Olopade, Olufunmilayo I. ; Eisen, Andrea ; Lerner-Ellis, Jordan ; Snyder, Carrie ; Kim, Shana J. ; Sun, Ping ; Narod, Steven A. / Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. In: British Journal of Cancer. 2019.
@article{593436a23c0241dfa37411b1e65307e0,
title = "Oestrogen receptor status and survival in women with BRCA2-associated breast cancer",
abstract = "Background: To evaluate the predictors of mortality, including ER status, in women with a BRCA2 mutation and breast cancer. Methods: Eligible participants were identified from within two longitudinal cohorts. These patients were selected because they were diagnosed with breast cancer between 1975 and 2015 and carried a BRCA2 mutation. Data were abstracted from the medical record and pathology report. We analysed the effects of ER status and other variables on breast cancer specific survival using a Cox proportional hazards model. Results: Three hundred ninety women with breast cancer and a BRCA2 mutation were included in the analysis. The mean follow-up time was 12.3 years (range 1–39 years) and 89 subjects died (22.8{\%}). In the multivariate analysis, women with ER-positive tumours were more likely to die than women with ER-negative tumours (HR 2.08, 95{\%} CI 0.99–4.36, p = 0.05), and this was of borderline significance. For the 233 women with ER-positive tumours the 20-year survival rate was 62.2{\%}, compared to 83.7{\%} for 58 women with ER-negative tumours (p = 0.03). Conclusions: The majority of women with a BRCA2 mutation present with ER-positive breast cancer, and for these women, prognosis may be worse than for BRCA2 carriers with ER-negative breast cancer.",
author = "Kelly Metcalfe and Lynch, {Henry T.} and Foulkes, {William D.} and Nadine Tung and Olopade, {Olufunmilayo I.} and Andrea Eisen and Jordan Lerner-Ellis and Carrie Snyder and Kim, {Shana J.} and Ping Sun and Narod, {Steven A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41416-019-0376-y",
language = "English (US)",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Oestrogen receptor status and survival in women with BRCA2-associated breast cancer

AU - Metcalfe, Kelly

AU - Lynch, Henry T.

AU - Foulkes, William D.

AU - Tung, Nadine

AU - Olopade, Olufunmilayo I.

AU - Eisen, Andrea

AU - Lerner-Ellis, Jordan

AU - Snyder, Carrie

AU - Kim, Shana J.

AU - Sun, Ping

AU - Narod, Steven A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: To evaluate the predictors of mortality, including ER status, in women with a BRCA2 mutation and breast cancer. Methods: Eligible participants were identified from within two longitudinal cohorts. These patients were selected because they were diagnosed with breast cancer between 1975 and 2015 and carried a BRCA2 mutation. Data were abstracted from the medical record and pathology report. We analysed the effects of ER status and other variables on breast cancer specific survival using a Cox proportional hazards model. Results: Three hundred ninety women with breast cancer and a BRCA2 mutation were included in the analysis. The mean follow-up time was 12.3 years (range 1–39 years) and 89 subjects died (22.8%). In the multivariate analysis, women with ER-positive tumours were more likely to die than women with ER-negative tumours (HR 2.08, 95% CI 0.99–4.36, p = 0.05), and this was of borderline significance. For the 233 women with ER-positive tumours the 20-year survival rate was 62.2%, compared to 83.7% for 58 women with ER-negative tumours (p = 0.03). Conclusions: The majority of women with a BRCA2 mutation present with ER-positive breast cancer, and for these women, prognosis may be worse than for BRCA2 carriers with ER-negative breast cancer.

AB - Background: To evaluate the predictors of mortality, including ER status, in women with a BRCA2 mutation and breast cancer. Methods: Eligible participants were identified from within two longitudinal cohorts. These patients were selected because they were diagnosed with breast cancer between 1975 and 2015 and carried a BRCA2 mutation. Data were abstracted from the medical record and pathology report. We analysed the effects of ER status and other variables on breast cancer specific survival using a Cox proportional hazards model. Results: Three hundred ninety women with breast cancer and a BRCA2 mutation were included in the analysis. The mean follow-up time was 12.3 years (range 1–39 years) and 89 subjects died (22.8%). In the multivariate analysis, women with ER-positive tumours were more likely to die than women with ER-negative tumours (HR 2.08, 95% CI 0.99–4.36, p = 0.05), and this was of borderline significance. For the 233 women with ER-positive tumours the 20-year survival rate was 62.2%, compared to 83.7% for 58 women with ER-negative tumours (p = 0.03). Conclusions: The majority of women with a BRCA2 mutation present with ER-positive breast cancer, and for these women, prognosis may be worse than for BRCA2 carriers with ER-negative breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=85061179604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061179604&partnerID=8YFLogxK

U2 - 10.1038/s41416-019-0376-y

DO - 10.1038/s41416-019-0376-y

M3 - Article

C2 - 30723304

AN - SCOPUS:85061179604

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

ER -